Abstract
Malignant hyperthermia (MH) is a rare but potentially lethal skeletal muscle disorder affecting calcium release channels. It is inherited in a mendelian autosomal dominant pattern with variable penetration. The initial clinical manifestations are of a hypermetabolic state with increased CO2 production, respiratory acidosis, increased temperature, and increased oxygen demands. If diagnosed late, MH progresses to multi–organ system failure and death. Current data suggest that mortality has improved to less than 5%. The gold standard for ruling out MH is the contracture test. Genetic testing is also available. MH-susceptible individuals should be clearly identified for safe administration of future anesthetics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 165-181 |
| Number of pages | 17 |
| Journal | Anesthesiology Clinics |
| Volume | 38 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2020 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019 Elsevier Inc.
Keywords
- Caffeine-halothane contracture test
- Charcoal filters
- Dantrolene
- Malignant hyperthermia
- MHAUS
Fingerprint
Dive into the research topics of 'Malignant Hyperthermia Update'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS